Amneal Pharmaceuticals, Inc. — Net Income by Fiscal Year
10 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/2f6f969b-2b51-4678-96a7-40f763189a6d/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $72.1M | 2025-01-01 – 2025-12-31 | evidence 0001723128-26-000011 |
| FY 2024 | $-116.9M | 2024-01-01 – 2024-12-31 | evidence 0001723128-26-000011 |
| FY 2023 | $-84.0M | 2023-01-01 – 2023-12-31 | evidence 0001723128-26-000011 |
| FY 2022 | $-270.6M | 2022-01-01 – 2022-12-31 | evidence 0001723128-23-000009 |
| FY 2021 | $13.2M | 2021-01-01 – 2021-12-31 | evidence 0001723128-22-000006 |
| FY 2020 | $67.8M | 2020-01-01 – 2020-12-31 | evidence 0001723128-22-000006 |
| FY 2019 | $-603.6M | 2019-01-01 – 2019-12-31 | evidence 0001723128-22-000006 |
| FY 2018 | $-19.7M | 2018-01-01 – 2018-12-31 | evidence 0001723128-19-000028 |
| FY 2017 | $0 | 2017-01-01 – 2017-12-31 | evidence 0001723128-19-000028 |
| FY 2016 | $0 | 2016-01-01 – 2016-12-31 | evidence 0001723128-19-000028 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Amneal Pharmaceuticals, Inc. — all facts · Revenue · Operating Income